CUSIP: 71426VAK4
Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Debt / DBCV 4.250% 4/0
-
Market price (% of par)
-
41.7%
-
Total 13F principal
-
$69,725,000
-
Principal change
-
$0
-
Total reported market value
-
$26,717,000
-
Number of holders
-
12
Quarterly Holders Quick Answers
What is CUSIP 71426VAK4?
CUSIP 71426VAK4 identifies 71426VAK4 - PERNIX THERAPEUTICS HLDGS IN - DBCV 4.250% 4/0 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2018
-
Previous quarter:
Q2 2018
Recent filing periods for CUSIP 71426VAK4:
Institutional Holders of PERNIX THERAPEUTICS HLDGS IN - DBCV 4.250% 4/0 as of Q3 2018
As of 30 Sep 2018,
PERNIX THERAPEUTICS HLDGS IN - DBCV 4.250% 4/0 was held by
12 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$69,725,000
in principal (par value) of the bond.
The largest 10 bondholders included
ARMISTICE CAPITAL, LLC, Broadfin Capital, LLC, Telemetry Investments, L.L.C., venBio Select Advisor LLC, Jefferies Group LLC, Aisling Capital LLC, ZAZOVE ASSOCIATES LLC, Bruce & Co., Inc., TENOR CAPITAL MANAGEMENT Co., L.P., and CITADEL ADVISORS LLC.
This page lists
12
institutional bondholders reporting positions
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.